Hepatitis D is a viral infection caused by the hepatitis D virus (HDV), which is a ribonucleic acid (RNA) virus that requires hepatitis B virus (HBV) for its replication. It attacks the liver and can cause both acute and chronic disease. Hepatitis D infection cannot occur in the absence of hepatitis B virus. The risk factors associated with hepatitis D includes hepatitis B infection, frequent blood transfusions and abuse injectable or intravenous (IV) drugs, such as heroin. Eiger BioPharmaceuticals, Inc. is in the process of developing Sarasar as a formulation of lonafarnib for the treatment of hepatitis D. Sarasar is a late-stage, orally active inhibitor of farnesyl transferase. Lonafarnib is an enzyme involved in modification of proteins through a process known as prenylation. Some of the companies having a pipeline of hepatitis D include Replicor Inc., Gilead Sciences, Inc. and others.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities, including information about clinical results, designations, collaborations, licencing, grants, technology and others.